Merck has entered a development agreement with US-based SFJ Pharmaceuticals Group to develop its investigational drug abituzumab for the treatment of metastatic colorectal cancer (mCRC).

The agreement reflects Merck’s strategic approach to collaborations, identifying those opportunities that can progress the company’s clinical stage assets through novel innovation models.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SFJ will sponsor a Phase II/III clinical trial to evaluate abituzumab in combination with Erbitux and chemotherapy in a first-line setting for high ανβ6-expressing patients with RAS wild‑type left‑sided mCRC.

SFJ CEO Robert DeBenedetto said: “Our expertise in oncology and renowned ability to successfully carry out various late stage clinical development projects is gaining wider acceptance and enables industry players like Merck to develop their promising assets by risk-sharing with us.”

“Together with SFJ, we aim to progress the understanding of the potential of abituzumab as a targeted treatment for patients suffering from mCRC.”

Merck has already completed Phase II trials of the drug in combination with Erbitux and chemotherapy in a second line all-comer population of KRAS wild-type mCRC patients.

During the trial, a subgroup of patients with overexpression of integrin αvβ6 were identified as potentially benefiting from the combination therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Merck executive board member and healthcare CEO Belén Garijo said: “Our collaboration with SFJ illustrates Merck’s increasing focus on strategic partnering in order to further diversify our development risks as well as enable a more efficient pipeline prioritisation.

“Together with SFJ, we aim to progress the understanding of the potential of abituzumab as a targeted treatment for patients suffering from mCRC.”